20 / 39
Volume 4
Nano Research & Applications
ISSN: 2471-9838
Page 79
JOINT EVENT
August 16-18, 2018 | Dublin, Ireland
&
12
th
Edition of International Conference on
Nanopharmaceutics and Advanced Drug Delivery
25
th
Nano Congress for
Future Advancements
Nano Congress 2018
&
Nano Drug Delivery 2018
August 16-18, 2018
Multifunctional bioinspired nanocarrier based targeted therapy for lung cancer
Mahavir B Chougule
University of Mississippi, USA
Statement of the Problem:
Despite an increased understanding of pathophysiology and advanced therapies, the success rate
in the treatment of lung cancer remains unsatisfactory. Conventional therapies are rarely successful due to limited amount of
drug reaching the tumor site even administered at a high dose and associated toxic effects. Therefore, site-specific targeted
delivery of therapeutically active agents to the tumor cells is the most crucial step for the effective treatment of lung cancer.
The aim is to develop aerosolized Celecoxib loaded lipid nanocarriers (Cxb-NLC) and evaluate
in vitro
and
in-vivo
anticancer
activity of as a single therapeutic agent and combined with intravenously administered Docetaxel (Doc) against non-small cell
lung cancer. Our approach is to deliver the chemodrugs using targeted biodegradable lipidic biomaterial based nanocarriers
via inhalation route of administration to tumor cells while sparing normal cells. The high-pressure homogenization was used
for nanocarrier preparation and characterized for its physicochemical characteristics. The
in vivo
A549 tumor model in Nu/
Nu mice was used to evaluate the efficacy. The particle size of Cxb-NLC was 217±20nm, while entrapment efficiency was >
90%. Cxb-NLC and Doc alone and in combination showed 25±4 %, 37±5 %, and 67±4 % reduction in tumor size respectively
compared to control. Proteomic analysis with combination treatment further revealed significantly decreased expression of
multiple pro-survival and pro-metastasis proteins. Cxb-NLC and Doc combination therapy showed significant reduction in
tumor growth which was further confirmed by proteomic analysis. The
in vitro
, lung cancer orthotopic tumor models studies
confirm the enhanced efficacy of developed targeted nanocarriers.
chougule@olemiss.eduNano Res Appl 2018, Volume 4
DOI: 10.21767/2471-9838-C3-015